The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.25
Bid: 44.50
Ask: 46.00
Change: -0.25 (-0.55%)
Spread: 1.50 (3.371%)
Open: 45.50
High: 45.75
Low: 45.25
Prev. Close: 45.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

Wed, 24th Feb 2021 11:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - Proceeding to full clinical valuation for its Covid-19 test to support a CE Mark, with a possible commercial launch of the test for professional use near the end of the first quarter of 2021. Chief Executive Alastair Smith says Avacta is close to fully establishing its supply chain for scalable manufacture of test kits and "making timely progress in instituting a quality management system to support the required ISO13485 accreditation for medical devices". The AffiDX SARS-CoV-2 lateral flow rapid antigen test is, as far as Avacta is aware, "the most sensitive S1 spike lateral flow test available". December 31 cash position GBP28 million, a little higher than market forecasts.

----------

Gooch & Housego PLC - Somerset-based optical components and systems maker - Notes improved levels of demand across industrial laser sector during the first four months of its financial year ending September 2021. This includes, in line with previously reported trends, continuing high levels of demand for fibre optics, hi-reliability fibre couplers as well as its Aerospace & Defence capabilities. Also sees strong growth from Life sciences. Recovering in industrial lasers led by Asian markets, though US and European markets now also showing "encouraging trends" while 5G rollout "has fuelled demand led growth, building on the previously reported recovery in semiconductors". A&D order book robust. Medial diagnostics demonstrating good growth with improves levels of demand for medical laser products, previously hurt by reduced non-Covid-19 procedures in financial 2020. Cash generation robust, net debt further shrinks in first four months of financial year despite payment of final earn out associated with an acquisition. January 31 order book GBP95.0 million, a little higher than the previous year's GBP94.1 million. Streamlining manufacturing sites, with all product lines at Glenrothes, Scotland facility transferred to new UK Precision Optics hub in Ilminster and Glenrothes site now closed. Outsourcing of Acousto Optic products from Ilminster to Asian contract manufacturer "progressing well" and set to complete by financial year end. Begins transferring production from St Asaph, Wales facility to Ilminster Precision Optics hub. Optical systems engineering and design centre to be retained in St Asaph. Target completion of both projects by current financial year end.

----------

Proactis Holdings PLC- Wetherby-based cash management software company - Expects to post a drop in revenue for the six months ended January 31 to GBP23.7 million from GBP24.5 million but with higher adjusted earnings before interest, tax, depreciation, and amortisation of GBP6.2 million versus GBP5.6 million the year before. Explains that its operating margins have improved after it restructures its management team and operating costs base. Says net bank debt at the end of January was GBP39.7 million, up from GBP37.1 million on July 31. Explains that its position has been hurt by a reduction in cash levels from its outsourced sourcing business as a consequence of lower trading volumes due to Covid-19 plus cash flow and upfront costs of the restructure. Expects to post a half-year performance in line with board expectations.

----------

Echo Energy PLC - Latin America focused upstream oil and gas company - Agrees, along with Santa Cruz Sur partners, to capital expenditure for upgrading and debottlenecking the existing liquids pipelines in the Santa Cruz Sur assets, located in onshore Argentina. This will accelerate a return to full oil production and bring remaining volumes, previously shut in the second quarter of 2020, back online. This follows an increase in demand, which resulted in improved pricing and more frequent oil sales. Pipeline upgrades will also grant additional capacity for production enhancement product in the future, which have been identified. Capital expenditure, net to Echo's 70% working interest in Santa Cruz Sur, will be around USD175,000 and will be injected by Echo to replace and upgrade parts of the infrastructure - mostly in the Chorillos, Campo Molino and Cerro Convento fields. Installation is expected to take around 45 days with 10 upgrade projects to be completed, upgrading a total of around 23 kilometres of pipeline and restoring gross daily liquids production to between 480 barrels of oil per day and 600 bopd, or 336bopd to 420 bopd net to Echo. In 2020, total cumulative production net to Echo from Santa Cruz Sur was 720,000 boe. From January

----------

Alba Mineral Resources PLC- mineral exploration and development company with assets in Greenland and the UK - Says it has planned the next phase of regional exploration for the Dolgellau gold exploration project in north Wales. The next phase of work over the field involves stream sediment sampling, which is designed to identify hard-rock gold sources upstream of sampling locations. This will be the first field work to take place over Alba's Gwynfynydd exploration licence area since the licence was warded in November 2020. Chair George Frangeskides, says: "For the first time, we will be expanding our regional exploration programme to cover our recently granted Gwynfynydd exploration licence. We are very optimistic about the prospects for finding new gold deposits in the Dolgellau gold field."

----------

Angling Direct PLC - Norwich, Norfolk-based fishing tackle and equipment retailer - Expects to post a 27% revenue increase for its financial year ended January 31 to GBP67.6 million from GBP53.2 million the year before despite closure of its retail stores and only being able to operate on a "call & collect" basis under lockdown rules. This growth results from online sales, up 40% to GBP35.3 million from GBP25.2 million with. Total store sales, including call & collect, rose 16% to GBP32.3 million from GBP27.9 million with the total number of stores increasing to 38 on January 31 from 34 the prior year and new stores contributed GBP2.2 million in sales. Forecasts pre IFRS-16 Ebitda of at least GP3.8 million for financial 2021 versus a GBP500,000 loss year-on-year. Cash position at January end GBP15.0 million, sharply rising from GBP5.9 million the year before. Not providing guidance for financial 2022 until full extent of Covid-19 disruption is known.

----------

IronRidge Resources Ltd - Australia-based minerals exploration company - Drilling progressing well at the Ewoyaa lithium project in Ghana, with around 4,1000 in 40 reverse circulation holes completed so far. Says visible coarse spodumene mineralisation has been observed in 36 holes to date, with maximum reported pegmatite internals up to 36 metres and approximating true width. Spodumene mineralisation has been observed in most pegmatite targets tested, with good continuity up to 300 metres along strike and down dip. Average pegmatite widths between 10 and 15 metres. So far, three of the seven pegmatite target zones have been drill tested and drilling is ongoing, with assays pending. Chief Executive Vincent Mascolo says: "This drilling programme is a key part of our work towards expanding the resource base on what is widely considered to be an industry-leading asset. We are now evaluating options to fast track the project to production to take advantage of the increasing demand for lithium and its role in the future growth of stored energy initiatives."

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 12:01

Avacta cancer drug candidate AVA6000 advances to fourth dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its fourth dose cohort.

Read more
21 Jul 2022 15:29

Avacta joint venture completes fresh funding round

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Thursday that AffyXell, its joint venture with Daewoong Pharmaceuticals, has completed a funding round to advance its lead mesenchymal stem cell (MSC) programme towards the clinic, and to develop its wider preclinical pipeline of cell therapies.

Read more
21 Jul 2022 12:17

Avacta joint venture completes funding for lead cell therapy programme

(Alliance News) - Avacta Group PLC on Thursday said that its joint venture AffyXell with Daewoong Pharmaceuticals Co Ltd has successfully completed a funding round.

Read more
30 Jun 2022 11:22

Avacta's partner LG Chem renews licence to develop Affimer platform

(Alliance News) - Avacta Group PLC said on Thursday that LG Chem Life Sciences has exercised its renewal option as part of an ongoing collaboration with the company, triggering a fee payment of USD2 million to Avacta.

Read more
29 Jun 2022 11:38

AIM WINNERS & LOSERS: Deltic rises on Shell deal; Windar down on delay

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
29 Jun 2022 10:21

Avacta shares up as cancer drug AVA6000 advances to third dose cohort

(Alliance News) - Avacta Group PLC said on Wednesday its candidate for multiple forms of cancer, AVA6000 Pro-doxorubicin, is advancing to its third dose cohort after "a positive review of the safety data" from the second cohort.

Read more
16 Jun 2022 16:03

UK shareholder meetings calendar - next 7 days

Friday 17 June 
Blackstone Loan Financing LtdAGM
boohoo Group PLCAGM
Directa Plus PLCAGM
Tesco PLCAGM
EnQuest PLCAGM
Octopus Renewables Infrastructure Trust PLCAGM
Monday 20 June 
Armadale Capital PLCAGM
Bank of Georgia Group PLCAGM
Globalworth Real Estate Investments LtdAGM
MetalNRG PLCAGM
Midatech Pharma PLCAGM
Silver Bullet Data Services Group PLCGM re fundraise
Venture Life Group PLCAGM
Tuesday 21 June 
1Spatial PLCAGM
Altus Strategies PLCAGM
Coca-Cola HBC AGAGM
FireAngel Safety Technology Group PLCAGM
HC Slingsby PLCAGM
HSS Hire Group PLCAGM
Mission Group PLCAGM
Novacyt SAAGM
Pendragon PLCAGM
RTW Venture Fund LtdAGM
Velocys PLCAGM
Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Zinnwald Lithium PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
16 May 2022 14:04

IN BRIEF: Avacta joint venture expands partnership with GenScript

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Says its joint venture AffyXell with Seoul, South Korea-based drug maker Daewoong Pharmaceutical Co Ltd expanded its partnership with GenScript ProBio. Says the partnership covers the process development and production of viral vectors required for the production of AffyXell's future cell therapy products. Adds that GenScript has now committed to take an equity position in AffyXell at a future funding round. The two companies will also collaborate in the area of business development, including potential out-licensing.

Read more
13 Apr 2022 17:33

Avacta increases shareholding in drug developer AffyXell to 22%

(Alliance News) - Avacta Group PLC said on Wednesday it increased its shareholding in its South Korean joint venture, AffyXell Therapeutics.

Read more
13 Apr 2022 13:57

Avacta triggers milestone in Daewoong joint venture

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Wednesday that a milestone equity payment has been triggered, resulting in an increase in its shareholding in AffyXell Therapeutics.

Read more
8 Apr 2022 16:17

Avacta joint venture enters new immune model collaboration

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Friday that AffyXell Therapeutics - its joint venture with Daewoong Pharmaceutical - has entered into a collaboration agreement with Chinese biological drugs developer Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).

Read more
8 Apr 2022 11:28

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
8 Apr 2022 10:37

Avacta joint venture to collaborate with Chinese biological company

(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.

Read more
6 Apr 2022 10:23

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends.

Read more
16 Mar 2022 13:02

Avacta offloads animal health unit in £2.3m deal

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Avacta Animal Health, for consideration of up to £2.3m.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.